A critical review of oxazolidinones: An alternative or replacement for glycopeptides and streptogramins?

Canadian Journal of Infectious Diseases

Volumn 12, Issue 6, 2001, Pages 379-390

  Zhanel, George G ^a   Schroeder, Coleen ^a   Vercaigne, Lavern ^a   Gin, Alfred S ^a   Embil, John ^a   Hoban, Daryl J ^a  

^a HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Glycopeptides; Linezolid; Oxzolidinones; Streptogramins

Indexed keywords

AZTREONAM; CEFPODOXIME PROXETIL; CEFTRIAXONE; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DICLOXACILLIN; EPEREZOLID; GLYCOPEPTIDE; LINEZOLID; METICILLIN; MONOAMINE OXIDASE INHIBITOR; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; STREPTOGRAMIN DERIVATIVE; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; CLINICAL TRIAL; DISTRIBUTION VOLUME; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; MEDICAL LITERATURE; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; REVIEW; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTE DISORDER;

EID: 0035715934     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/260651     Document Type: Review

References (85)

1. Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721
2. Toxicity of Dup-105
3. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections
4. Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds
5. Antibacterials. Synthesis a structure-activity studies of 3-aryl-2- oxooxazolidines. 1. The "B" group
6. Antibacterials. Synthesis and structure-activity studies of 3-aryl-2- oxooxazolidines. 4. Multiply-substituted aryl derivatives
7. Design, synthesis, and evaluation of novel oxazolidinone antibacterial agents active against multidrug-resistant bacteria
8. Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring
9. Nitrogen-carbon-linked (Azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis
10. Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl) oxazolidinones with expanded activity against the fastidious Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis
11. Mechanism of action oxazolidinones: Effects of linezolid and eperezolid on translation reactions
12. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin
13. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors
14. Bacterial protein synthesis: The effects of antibiotics
15. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
16. Ribosomes from a oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay
17. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
18. Development of linezolid resistant Enterococcus faecium in two compassionate use program patients treated with linezolid
19. In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis
20. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center
21. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones
22. In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents
23. In-vitro microbiological activities of DuP105 and DuP721, novel synthetic oxazolidinones
24. In vitro activities in new oxazolidinone antimicrobial agents against enterococci
25. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species
26. In-vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae
27. Comparative in-vitro activities of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP721 and DuP105 against methicillin and gentamicin resistant Staphylococcus aureus
28. Comparative in vitro activity of the new oxazolidinones DuP721 and DuP105 against staphylococci and streptococci
29. In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105
30. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci
31. The in-vitro activity of linezolid (U-100766) and tentative breakpoints
32. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans
33. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae
34. Vancomycin
35. Quinupristin/dalfopristin: A review of its use in the management of serious Gram-positive infections
36. Antibiotics for Gram-positive bacterial infections: Vancomycin, teicoplanin, quinupristin/dalfopristin and linezolid
37. Antimicrobial activity of quinupristin/dalfopristin (RP 59500 Synercid) tested over 28,000 recent clinical isolates from 200 medical centres in the United States and Canada
38. In-vitro activity of oxazolidinones against Mycobacterium avium complex
39. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model
40. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
41. Linezolid safety, tolerance and pharmacokinetics following intravenous dosing twice daily for 7.5 days
42. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days
43. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis
44. Pharmacokinetics of linezolid in patients with liver disease
45. Clinical pharmacokinetics of vancomycin
46. Assessment of absolute bioavailability and the evaluation of the effect of food on oral bioavailability of linezolid
47. U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration
48. In vitro metabolism of linezolid (PNU-100766): Lack of induction or inhibition of cytochrom P450 enzymes and studies on the mechanism of formation of the major human metabolite PNU-142586
49. Metabolism and excretion of the oxazolidinone antibiotic linezolid (PNU-100766) following oral administration of [14-C]PNU-100766 to healthy human volunteers
50. Effect of age and gender on linezolid pharmacokinetics
51. Choosing an antibiotic on the basis of pharmacodynamics
52. Pharmcokinetics and pharmacodynamics of newer macrolides
53. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
54. Pharmacokinetic contributions to post-antibiotic effects: Focus on aminoglycosides
55. The new fluoroquinolones: A critical review
56. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
57. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
58. Pharmacodynamic activity of a new oxazolidinone, linezolid, in an animal infection model
59. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci
60. Expression of virulence factors by Gram-positive cocci exposed to sub-MIC levels of linezolid
61. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections
62. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia
63. Linezolid is effective against penicillin-resistant Streptococcus pneumoniae (PRSP) in hospitalized patients with community-acquired pneumonia
64. Linezolid in the treatment of community-acquired pneumonia: The results of phase II and phase III studies
65. Efficacy of linezolid in pneumonia due to penicillin intermediate and resistant Streptococcus pneumoniae
66. Linezolid for the treatment of community- or hospital-acquired pneumonia caused by Staphylococcus aureus: Results of four randomized phase III trials
67. Linezolid in the treatment of outpatients with community acquired pneumonia: European results
68. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized double-blind multicentre study
69. Comparison of linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: Results from a multinational phase II trial
70. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft-tissue infections
71. Linezolid in the treatment of cellulitus and erysipelas: Combined results from four phase III multinational clinical trials
72. Comparison of length of hospital stay for patients known or suspected methicillin-resistant Staphylococus species infections treated with linezolid or vancomycin: A randomized multicentre trial
73. Safety and tolerance of linezolid in phase II trials
74. Outcomes with linezolid (lzd) from an ongoing compassionate use (cu) trial of patients (pts) with significant, resistant, Gram-positive infections
75. Safety and tolerance of linezolid: Adverse events reported in phase III trials
76. Although a novel microtiter-plate assay demonstrates that linezolid (PNU-100766) is a weak, competitive reversible) inhibitor of human monoamine oxidase (MAO A), no clinical evidence of MAO A inhibition in clinical trials has been observed
77. Linezolids effects on early hospital discharge in hospitalized patients with complicated skin and soft tissue infections (cSSTI) under varying rates of methicillin-resistant staphylococcus (MRS) infection: Analysis of results from two randomized clinical trials (RCTs)
78. Infections due to vancomycin resistant Enterococcus faecium resistant to linezolid